Bernie Sanders wants HHS to look into the price of Eisai’s newly approved Alzheimer’s drug

Sen­ate Health Com­mit­tee Chair Bernie Sanders (I-VT) is hav­ing no qualms about his pur­suit of low­er­ing drug prices.

First, he went af­ter the top in­sulin man­u­fac­tur­ers with a grilling, and then he pledged to block Pres­i­dent Joe Biden’s NIH di­rec­tor nom­i­nee Mon­i­ca Bertag­nol­li if the ad­min­is­tra­tion doesn’t do more to low­er drug prices (even af­ter the In­fla­tion Re­duc­tion Act passed). And now he’s call­ing on HHS Sec­re­tary Xavier Be­cer­ra to take a clos­er look at the price of Ei­sai and Bio­gen’s new, ful­ly ap­proved Alzheimer’s drug Leqem­bi (lecanemab).

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN